C M Parsons1, N Harvey1,2, L Shepstone3, J A Kanis4,5, E Lenaghan3, S Clarke6, R Fordham3, N Gittoes7, I Harvey3, R Holland3, N M Redmond6,8, A Howe3, T Marshall3, T J Peters6, D Torgerson9, T W O'Neill10,11, E McCloskey4,12,13, C Cooper14,15,16. 1. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK. 2. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. 3. University of East Anglia, Norwich, UK. 4. Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. 5. Institute for Health and Ageing, Catholic University of Australia, Melbourne, Australia. 6. Bristol Medical School, University of Bristol, Bristol, UK. 7. Centre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK. 8. NIHR CLAHRC West, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. 9. University of York, York, UK. 10. Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. 11. NIHR Manchester Biomedical Research Centre, Manchester University Hospitals Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 12. Mellanby Centre for Bone Research, Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK. 13. Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK. 14. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK. cc@mrc.soton.ac.uk. 15. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. cc@mrc.soton.ac.uk. 16. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. cc@mrc.soton.ac.uk.
Abstract
In the large community-based SCOOP trial, systematic fracture risk screening using FRAX® led to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care. INTRODUCTION: In the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM). METHODS:SCOOP was a primary care-based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70-85 years) were randomised to either usual NHS care, or assessment using the FRAX®tool ± dual-energy X-ray absorptiometry (DXA), with medication recommended for those found to be at high risk of hip fracture. Self-reported AOM use was obtained by postal questionnaires at 6, 12, 24, 36, 48 and 60 months. Analysis was limited to those who initiated AOM during follow-up. Logistic regression was used to explore baseline determinants of adherence (good ≥ 80%; poor < 80%). RESULTS:The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01). CONCLUSIONS: Systematic fracture risk screening using FRAX® leads to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care.
RCT Entities:
In the large community-based SCOOP trial, systematic fracture risk screening using FRAX® led to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care. INTRODUCTION: In the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM). METHODS: SCOOP was a primary care-based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70-85 years) were randomised to either usual NHS care, or assessment using the FRAX® tool ± dual-energy X-ray absorptiometry (DXA), with medication recommended for those found to be at high risk of hip fracture. Self-reported AOM use was obtained by postal questionnaires at 6, 12, 24, 36, 48 and 60 months. Analysis was limited to those who initiated AOM during follow-up. Logistic regression was used to explore baseline determinants of adherence (good ≥ 80%; poor < 80%). RESULTS: The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01). CONCLUSIONS: Systematic fracture risk screening using FRAX® leads to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care.
Authors: A Diez-Perez; K E Naylor; B Abrahamsen; D Agnusdei; M L Brandi; C Cooper; E Dennison; E F Eriksen; D T Gold; N Guañabens; P Hadji; M Hiligsmann; R Horne; R Josse; J A Kanis; B Obermayer-Pietsch; D Prieto-Alhambra; J-Y Reginster; R Rizzoli; S Silverman; M C Zillikens; R Eastell Journal: Osteoporos Int Date: 2017-01-16 Impact factor: 4.507
Authors: Clare L Emmett; Niamh M Redmond; Tim J Peters; Shane Clarke; Lee Shepstone; Elizabeth Lenaghan; Alison R G Shaw Journal: Fam Pract Date: 2011-09-09 Impact factor: 2.267
Authors: Samuel Hawley; Jose Leal; Antonella Delmestri; Daniel Prieto-Alhambra; Nigel K Arden; Cyrus Cooper; M Kassim Javaid; Andrew Judge Journal: J Bone Miner Res Date: 2016-07-04 Impact factor: 6.741
Authors: Jane A Cauley; Rowan T Chlebowski; Jean Wactawski-Wende; John A Robbins; Rebecca J Rodabough; Zhao Chen; Karen C Johnson; Mary Jo O'Sullivan; Rebecca D Jackson; JoAnn E Manson Journal: J Womens Health (Larchmt) Date: 2013-10-16 Impact factor: 2.681
Authors: David A Turner; Rebekah Fong Soe Khioe; Lee Shepstone; Elizabeth Lenaghan; Cyrus Cooper; Neil Gittoes; Nicholas C Harvey; Richard Holland; Amanda Howe; Eugene McCloskey; Terence W O'Neill; David Torgerson; Richard Fordham Journal: J Bone Miner Res Date: 2018-02-22 Impact factor: 6.741
Authors: L Shepstone; R Fordham; E Lenaghan; I Harvey; C Cooper; N Gittoes; A Heawood; T J Peters; T O'Neill; D Torgerson; R Holland; A Howe; T Marshall; J A Kanis; E McCloskey Journal: Osteoporos Int Date: 2012-10 Impact factor: 4.507
Authors: J Compston; A Cooper; C Cooper; N Gittoes; C Gregson; N Harvey; S Hope; J A Kanis; E V McCloskey; K E S Poole; D M Reid; P Selby; F Thompson; A Thurston; N Vine Journal: Arch Osteoporos Date: 2017-04-19 Impact factor: 2.617
Authors: P Chotiyarnwong; E V McCloskey; N C Harvey; M Lorentzon; D Prieto-Alhambra; B Abrahamsen; J D Adachi; F Borgström; O Bruyere; J J Carey; P Clark; C Cooper; E M Curtis; E Dennison; M Diaz-Curiel; H P Dimai; D Grigorie; M Hiligsmann; P Khashayar; E M Lewiecki; P Lips; R S Lorenc; S Ortolani; A Papaioannou; S Silverman; M Sosa; P Szulc; K A Ward; N Yoshimura; J A Kanis Journal: Arch Osteoporos Date: 2022-06-28 Impact factor: 2.879